Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Useful Contacts |
  6. Site Map |
  7. Help

  1. Font size

    Reduce font size Increase font size  
 
 

Site Map

Contact us

AUSTRALIA

Sanofi
Talavera Corporate Centre
Building D
12-24 Talavera Road
Macquarie Park, NSW 2113
+61 (0)2 8666 2000

NEW ZEALAND

Sanofi
James & Wells Tower
Part Level 8, 56 Cawley St
Ellerslie, Auckland
+64 (0)9 580 1810

Content :

Site Map

  1. About Us
    1. Pharmaceuticals
    2. Consumer Healthcare
    3. Vaccines
    4. Rare diseases
  2. Our Activities
    1. Pharmaceutical Division
    2. Consumer Healthcare
      1. OTC
      2. Nutraceuticals
    3. Vaccines
  3. Our Social Responsibility
    1. Patient 21
    2. People 21
    3. Ethics 21
    4. Planet 21
    5. Sponsorships
  4. Press Room
    1. News 2013
    2. News 2012
    3. News 2011
    4. News 2010
    5. News 2009
    6. News 2008
    7. News 2007
    8. News 2006
    9. News 2005
  5. Careers
    1. Search & Apply
    2. Working at Sanofi
    3. Diversity
    4. Career Rewards
      1. Compensation and Benefits
      2. Performance Management
      3. Learning and development
      4. Supporting our community
    5. FAQs
  6. Business Development

Module :

Corporate information

Corporate information

 

Latest News

March 13, 2013

Important information regarding the Supply of Seprafilm® Adhesion Barrier

October 15, 2012

SUPPLY STATUS: ImmuCyst ® BCG Bacillus Calmette-Guerin (BCG) 6.6 - 19.2 x 100000000 CFU powder for injection vial, AUST R 168005